Terashima K, Muraoka O, Ono M
Research Laboratories, Roussel Morishita Co., Ltd., Shiga, Japan.
Chem Pharm Bull (Tokyo). 1995 Nov;43(11):1985-91. doi: 10.1248/cpb.43.1985.
To explore the mechanism of the gastric antisecretion activity of ethyl 2-[(1H-benzimidazol-2-yl)sulfinylmethyl]- 4-dimethylamino-5-pyrimidinecarboxylate (5), a potential H+/K(+)-ATPase inhibitor, in the acid compartment of parietal cells, its reaction with some alkylthiols in the presence of hydrochloric acid was investigated. Upon treatment with 2-mercaptoethanol under acidic conditions, 5 gave a characteristic 1:2 adduct, ethyl 4-[2-(2-hydroxyethyldithio)- 1-(2-hydroxyethylthio)ethylidenamino]pyrimido[1,2-a]benzimid azole-3- carboxylate (6), instead of providing a disulfide of type 3, 2-(2-alkyldithiomethylpyridino)benzimidazolide, the product predicted to be formed according to the reaction mechanism of common H+/K(+)-ATPase inhibitors, such as omeprazole or lansoprazole, with mercaptans. With a large excess of 2-mercaptoethanol, 5 provided 2-(2-hydroxyethylthio)-1H-benzimidazole (8) and ethyl 4-dimethylamino-2-(2-hydroxyethyldithio)-5-pyrimidinecarboxylat e (9) as well as 6. The transformation mechanisms and their implications are discussed.
为了探究潜在的H⁺/K⁺-ATP酶抑制剂2-[(1H-苯并咪唑-2-基)亚磺酰基甲基]-4-二甲基氨基-5-嘧啶羧酸乙酯(5)在壁细胞酸性区室中的胃抗分泌活性机制,研究了它在盐酸存在下与一些烷基硫醇的反应。在酸性条件下用2-巯基乙醇处理时,5生成了一种特征性的1:2加合物,即4-[2-(2-羟乙基二硫代)-1-(2-羟乙硫基)亚乙基氨基]嘧啶并[1,2-a]苯并咪唑-3-羧酸乙酯(6),而不是按照常见的H⁺/K⁺-ATP酶抑制剂如奥美拉唑或兰索拉唑与硫醇的反应机制所预测生成的3,2-(2-烷基二硫代甲基吡啶基)苯并咪唑二硫化物。在大量过量的2-巯基乙醇存在下,5生成了2-(2-羟乙硫基)-1H-苯并咪唑(8)、4-二甲基氨基-2-(2-羟乙基二硫代)-5-嘧啶羧酸乙酯(9)以及6。对转化机制及其意义进行了讨论。